Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
ConclusionsTreatment with ELAR does not increase the risk of cardiovascular events and may reduce all-cause mortality.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
More News: Byetta | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Victoza